文献速递胸部肿瘤

HER-2基因变异非小细胞肺癌的临床病理、分子特征及预后分析

[Clinicopathological, molecular characteristics and prognostic analysis of non-small cell lung cancer with HER-2 genetic variations].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2026-01-01

Exon20突变常见于女性且侵袭性较低;p.A270S突变可能与恶性表型相关。

要点

  • HER-2变异在NSCLC中占5.3%,以突变为主(86.5%),其中Exon20突变63例。
  • HER-2扩增与更大肿瘤、淋巴结转移、远处转移、高TNM分期及不良预后相关。
  • p.A270S突变16例中11例为TNM晚期,5例死亡,可能与恶性表型相关。

核心结论

  • HER-2不同变异类型(突变/扩增)呈现独特的临床病理与分子特征,HER-2扩增患者预后较差,p.A270S突变可能与肿瘤恶性表型相关。

主要发现

  • 148例HER-2变异中,128例为突变(86.5%,含63例Exon20突变),16例为扩增(10.8%),4例同时存在突变和扩增(2.7%)。
  • 与HER-2突变相比,HER-2扩增患者更易出现肿瘤增大、淋巴结转移、远处转移和TNM分期较高(均P<0.05)。
  • HER-2突变中,Exon20突变常见于女性,且肿瘤较小、淋巴结转移和远处转移风险更低(均P<0.05)。
  • Cox回归分析提示HER-2扩增、肿瘤增大、淋巴结转移、远处转移和高TNM分期与预后不良相关(P<0.05)。
  • Exon20突变几乎不与其他基因共变异,非Exon20突变常伴随其他基因变异,常见EGFR突变(55.4%,36/65);p.A270S突变16例中11例为TNM晚期(68.8%,11/16),5例死亡。

临床怎么用

  • 对NSCLC患者进行HER-2变异分型检测有助于识别预后较差亚群,为个体化治疗提供参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the clinicopathological and molecular characteristics of non-small cell lung cancer (NSCLC) with human epidermal growth factor receptor 2 (HER-2) variations (including mutations and amplifications) and their correlation with prognosis. Methods: Clinicopathological data of NSCLC patients with HER-2 variations who underwent targeted next-generation sequencing (NGS) at Ningbo Clinical Pathology Diagnostic Center from September 2022 to June 2024 were collected. The clinicopathological and molecular features were retrospectively analyzed, and a literature review was conducted. Results: Among 2 795 NSCLC patients, HER-2 variations were identified in 148 cases (5.3%, 148/2 795). Of these, 128 cases had HER-2 mutations [86.5%, 128/148, including 63 exon 20 (Exon20) mutations], 16 cases had HER-2 amplifications (10.8%, 16/148), and 4 cases had concurrent HER-2 mutation and amplification (2.7%, 4/148). Compared with the HER-2 mutation group, patients with HER-2 amplification were more likely to have larger tumor size, lymph node metastasis, distant metastasis and higher TNM stage (all P<0.05). Among HER-2 mutations, Exon 20 mutations were more common in females and associated with lower risks of larger tumor size, lymph node metastasis and distant metastasis (all P<0.05). Cox regression analysis indicated that HER-2 amplification, larger tumor size, lymph node metastasis, distant metastasis and higher TNM stage were associated with poor prognosis (P<0.05). Molecular analysis revealed that Exon20 mutations rarely co-occurred with other gene variations, whereas non-Exon20 mutations were frequently accompanied by other genetic alternations, most commonly epidermal growth factor receptor (EGFR) mutations (55.4%, 36/65). In addition, 16 cases of HER-2 p.A270S mutation were identified, of which 11 were at advanced TNM stage (68.8%, 11/16), and 5 patient died. Conclusions: Different types of HER-2 variations (mutations/amplifications) exhibit distinct clinicopathological and molecular characteristics. Patients with HER-2 amplification have a poor prognosis, and the HER-2 p.A270S mutation may be associated with malignant phenotypes of NSCLC. It is necessary to integrate the characteristics of HER-2 variations to provide references for individualized treatment.. 目的: 分析人表皮生长因子受体2(HER-2)变异(包括突变和扩增)相关非小细胞肺癌(NSCLC)的临床病理、分子特征及与预后的相关性。 方法: 收集2022年9月至2024年6月宁波市临床病理诊断中心行靶向二代测序的伴有HER-2基因变异的NSCLC患者的临床病理资料,回顾性分析其临床病理特征及分子特征。 结果: NSCLC患者共2 795例,发现HER-2基因变异148例(5.3%,148/2 795),其中128例为HER-2突变[86.5%,128/148,包括63例20号外显子(Exon20)突变],16例为HER-2扩增(10.8%,16/148),4例同时存在HER-2突变和扩增(2.7%,4/148)。与HER-2突变相比,HER-2扩增患者更易出现肿瘤增大、淋巴结转移、远处转移和TNM分期较高(P<0.05);HER-2突变中,Exon-20突变常见于女性,且肿瘤较小、淋巴结转移和远处转移风险更低(P<0.05)。单因素Cox回归分析提示,HER-2扩增、肿瘤增大、淋巴结转移、远处转移和高TNM分期与患者预后不良相关(P<0.05)。分子特征显示,Exon20突变几乎不与其他基因共变异,而非Exon20突变常伴随其他基因变异,常见表皮生长因子受体突变(55.4%,36/65)。此外,检出16例HER-2 p.A270S突变,其中11例为TNM晚期(68.8%,11/16),5例患者死亡。 结论: HER-2不同变异类型(突变/扩增)呈现独特的临床病理与分子特征,其中HER-2扩增患者预后较差,p.A270S位点突变可能与肿瘤恶性表型相关。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang YJ, Xu JY, Zhang HZ, et al. [Clinicopathological, molecular characteristics and prognostic analysis of non-small cell lung cancer with HER-2 genetic variations]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42764221. doi:10.3760/cma.j.cn112152-20251218-00621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。